Navigation Links
Right first time: Pioneering new methods of drug manufacture
Date:11/11/2009

Engineers at the University of Leeds have developed a simple technology which can be used in existing chemical reactors to ensure "right first time" drug crystal formation.

Ensuring drug crystals are formed correctly is crucial to their efficacy and the efficiency of pharmaceutical manufacturers' operations. Using self-assembled monolayers, the team has been able to show that crystals form into their desired product form with the correct shape and particle structure, without the usual problems of polymorphism which results in huge losses to the pharmaceutical sector each year.

"If you imagine the way that oil sits on top of water, that's similar to how the monolayer works," says Professor Kevin Roberts of University's Faculty of Engineering. "We've shown that we can produce a well-defined crystal structure using a self-assembled monolayer bound onto a metal substrate within a regular reactor. This is exciting stuff, because it's a relatively simple system, but could make a huge difference in the efficiency of drug manufacture."

One of the first stages of the crystallisation process is called nucleation. During nucleation, particles are introduced into a reactor to encourage the formation of crystals. However, the way in which this is currently carried out is difficult to control and can often lead to the wrong shape, size or structure of drug crystal, something which affects the usefulness and efficacy of the compound.

The new system proven to work by the Leeds team, working alongside Ana Kwokal from Croatian pharmaceutical company PLIVA, has shown that introducing a self-assembled monolayer a layer of self-organising molecules that is attractive to the substance being crystallised into a reactor enables consistent crystal formation.

Professor Roberts says: "Because this is a really simple solution to ensuring consistent crystallisation, it has huge potential commercially. Our next steps are to make sure it's just as efficient on an industrial scale."

This work draws on previous research and experimental systems developed through the Chemicals Behaving Badly II initiative, an Engineering and Physical Sciences Research Council (EPSRC) programme which includes universities and industrial partners.


'/>"/>

Contact: Clare Elsley
Clare@campuspr.co.uk
44-113-258-9880
University of Leeds
Source:Eurekalert

Related medicine news :

1. Physicians for Human Rights Offers Training in Crime Scene Documentation
2. Bright Horizons Named One of Boston Globe 100s Top Places to Work
3. Good Sleepers More Likely to Eat Right
4. Mom was right: Nice guys dont always finish last
5. Rights Tracker Completes Fundraising
6. Lloyd Wright's Alternative Medicine Marketing Only Blueberry Extract with 45% of Hepatitis C Inhibitor Proanthocyanidin
7. Morphotek(R), Inc. Announces a Licensing Deal With Centocor Ortho Biotech Inc. for Exclusive Development and Commercialization Rights for a Therapeutic Monoclonal Antibody
8. AHIP Is Right, and May Be Low
9. Researchers discover mechanism that helps humans see in bright and low light
10. Go Healthy Secures Nationwide Distributorship Rights to Patented Drinking Water
11. Right Now Sale/Leaseback May Be the Only Option to Obtain Cash and a Healthier Balance Sheet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
Breaking Medicine Technology: